CANOPUS BIOPHARMA INC
A pharmaceutical research company that has discovered an effective and affordable treatment for Dengue fever and Hepatitis C.
- Stage Product In Development
- Industry Biotechnology
- Location Upper Coomera, Queensland, Australia
- Currency USD
- Founded July 1997
- Employees 10
- Website canopusbiopharma.com
Company Summary
Canopus BioPharma has developed an effective and affordable treatment for Hepatitis C, Dengue fever and a number of other infections.
The Company raised $14.5 million over the past seven years and has a Phase II report that confirms their Mogroside IV treatment is very effective in reducing Hepatitis C. It has also been tested to treat Dengue fever.
Canopus are now looking to raise up to US$6 million to complete patient trials for Dengue.
Team
-
Peter Michael O'NeillChairman
Peter has held executive and senior management positions for more than 30 years with various national and international organisations and was previously Managing Director of
a public company listed on the ASX that specialised in commercialising new technologies.
He has been Chairman of two companies and Managing Director of five other private companies. He is currently chairman of two companies and has been a director on 15 other company boards
Advisors
-
John Toigo, ClarkeKann SolicitorsLawyerUnconfirmedBusiness Result AccountantsAccountantUnconfirmed
Previous Investors
-
Family and FriendsUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.